BNO

BNO is “All In” for Philadelphia's Post-Pandemic Recovery

Retrieved on: 
Wednesday, November 15, 2023
YPO, Creativity, Heart, BNO, Young Presidents' Organization

This decision underscores BNO's dedication to investing in the Philadelphia community as it continues to rebound from the challenges posed by the global pandemic.

Key Points: 
  • This decision underscores BNO's dedication to investing in the Philadelphia community as it continues to rebound from the challenges posed by the global pandemic.
  • For nearly a decade, BNO has called Philadelphia its home, formerly as the Garfield Group, while also proudly serving clients from its two other locations in Somerville, New Jersey, and Saint Petersburg, Florida.
  • BNO's Old City lease renewal signifies a strong vote of confidence in Philadelphia's potential and reaffirms BNO's unwavering commitment to the regions they serve.
  • In fact, Philadelphia is the headquarters for the agency’s public relations team, which has grown exponentially in recent years.

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Retrieved on: 
Wednesday, August 23, 2023
Clinician Administered PTSD Scale, ISI, Central nervous system, Depression, BNC210, Official List, FOR, Montgomery–Åsberg Depression Rating Scale, Anxiety, SDS, Sleep, BNO, SAD, Australian Securities Exchange, DSM-IV codes, Hamilton Anxiety Rating Scale, Phase 3, Patient, Insomnia, Social anxiety disorder, United Kingdom, PGI, CGI, DSM-5, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Bionomics, PTSD

“I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study.

Key Points: 
  • “I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study.
  • The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023.
  • Additionally, Bionomics is scheduled to delist from the Official List of the Australian Securities Exchange on 28 August 2023.
  • The Company will remain an Australian incorporated company and will maintain its listing of ADSs on Nasdaq under the trading symbol ‘BNOX’.

BNO Celebrates Executive Milestones and Decades of Innovation

Retrieved on: 
Thursday, August 3, 2023
Workforce, Powell, Indian Telly Awards, BNO, Walker, Thought, Prince of Wales's Intelligence Community Awards, Chairperson, Johnson & Johnson, AI, SVP, 100 Best Workplaces in Europe, Management

SOMERVILLE, N.J., Aug. 3, 2023 /PRNewswire/ -- With more than four decades of innovation, BNO proudly celebrates two significant employee anniversaries. George Jackus, senior vice president of creative, commemorated 30 years with the agency on July 8 and Rachelle Powell, SVP of client engagement and strategy, celebrated 18 years on July 29. Both started their careers with the agency in the heat of the summer and have been fired up about the creative innovation at BNO ever since. Jackus was fresh out of college when he came aboard as a graphic designer back in 1993 and Powell joined as an account executive after relocating from Canada in 2005.  

Key Points: 
  • SOMERVILLE, N.J., Aug. 3, 2023 /PRNewswire/ -- With more than four decades of innovation, BNO proudly celebrates two significant employee anniversaries.
  • Both started their careers with the agency in the heat of the summer and have been fired up about the creative innovation at BNO ever since.
  • Decades of innovation continue to inspire agency leaders, as BNO celebrates milestone anniversaries.
  • Such inspired talent like Jackus and Powell drives innovation in agency culture and in the agency's work.

Quarterly Activities and Cashflow Report

Retrieved on: 
Monday, July 31, 2023
Psychopharmacology, Regulation of tobacco by the U.S. Food and Drug Administration, Employment, Central nervous system, BNC210, Quarter, Post-traumatic stress disorder, Comptroller, Audit, American depositary receipt, Delisting, F-3, Educational Strategy for Developing Societies, BNO, ASX, SAD, Research, Bionomics, CNS, Sale, Development, ATM, Prospectus, Patient, Form, CFO, FDA, Society, Conference, Food, PTSD, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Online shopping, Cantor

On 28 April 2023, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2023.

Key Points: 
  • On 28 April 2023, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2023.
  • Bionomics may determine to sell some, all, or none of the ADSs under the ATM Program and may terminate the ATM Program at its discretion.
  • Start-up activities for a planned Phase 3 trial of BNC210 in SAD are underway.
  • A copy of the full release, including a copy of the ASX Appendix 4C Cashflow Report can be found on the Company's website.

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

Retrieved on: 
Tuesday, July 25, 2023
Central nervous system, BNC210, American depositary receipt, ASX, BNO, SAD, Australian Securities Exchange, Bionomics, CNS, Patient, Social anxiety disorder, PTSD, Acute stress disorder

“Bionomics is approaching several very important value-inflection milestones for our late-stage clinical development program with BNC210, a first and best-in class α7 nicotinic receptor negative allosteric modulator under evaluation in patients with Social Anxiety Disorder (SAD) and Post-Traumatic Stress Syndrome (PTSD), in the coming quarters,” said Spyros Papapetropoulos, M.D.

Key Points: 
  • “Bionomics is approaching several very important value-inflection milestones for our late-stage clinical development program with BNC210, a first and best-in class α7 nicotinic receptor negative allosteric modulator under evaluation in patients with Social Anxiety Disorder (SAD) and Post-Traumatic Stress Syndrome (PTSD), in the coming quarters,” said Spyros Papapetropoulos, M.D.
  • Ph.D., Bionomics’ President and CEO; “As we continue our transformation to a U.S.-focused organization, we would like to deepen our engagement with the broadest range of potential investors and maximize Bionomics’ access to capital and financing opportunities while reducing costs and compliance obligations associated with a dual listing.
  • All information will be made available at https://ir.bionomics.com.au/ .
  • FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Retrieved on: 
Monday, July 3, 2023
Newton, Danforth, BS, Central nervous system, Therapy, Chairperson, Senior, KV3, BNC210, Comptroller, Biogen, Business operations, Audit, Neuroacanthocytosis, Connor, Drug, Boston, Educational Strategy for Developing Societies, BNO, ASX, MBA, Boston University, CNS, Development, Plasma protein binding, Strategic business unit, Newton-Wellesley Hospital, Patient, Vulnerability and Risk Committee, CPA, IND World's Fair Line, Hospital, Shirin David, KPMG, National Braille Association, Pharmaceutical industry, Management, Online shopping, Bionomics

Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.

Key Points: 
  • Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.
  • Mr. Fisher commented, “On behalf of the Board, I would like to express my excitement for Bionomics’ prospects and confidence in the team being assembled.
  • “Collectively, Tim, Julie, and Atul bring over 50+ years of experience in the biopharma sector, and diverse expertise in developing and commercializing drug products.
  • His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice.

Bionomics to Present at Upcoming June Investor Conferences

Retrieved on: 
Thursday, June 15, 2023
Central nervous system, BNO, Patient, Bionomics, Pharmaceutical industry, Online shopping

ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June:

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June:
    Presentation format: Panel discussion titled “Mental Health, More Critical Than Ever”
    Presentation date and time: On demand beginning at 7:00 am ET on June 26, 2023
    Links to access webcasts for select events, when available, will be posted to Bionomics’ website on the Events page of the Investors section.
  • FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Tuesday, May 30, 2023
Central nervous system, BNC210, Anxiety, Acute, Psychopharmacology, SAD, BNO, NAM, CNS, ASCP, Annual general meeting, Social anxiety disorder, Society, Pharmaceutical industry, Bionomics

The presentation will include previously announced data from Phase 2 PREVAIL study of BNC210 for the acute treatment of SAD, which support the late-stage development of the drug for this indication.

Key Points: 
  • The presentation will include previously announced data from Phase 2 PREVAIL study of BNC210 for the acute treatment of SAD, which support the late-stage development of the drug for this indication.
  • Collectively, these analyses further support BNC210’s potential as a non-sedating anxiolytic for the acute treatment of SAD and may inform future registrational trial designs, including the selection of endpoints and population.
  • “We look forward to discussing these results with the global psychopharmacology community at ASCP, especially as we prepare for an FDA End of Phase 2 meeting to discuss a registrational program in SAD.
  • Title: A Phase 2, Double-Blind, Placebo-Controlled Study for BNC210, an alpha7 Nicotinic Receptor Negative Allosteric Modulator (NAM) for the Acute Treatment of Social Anxiety Disorder (PREVAIL): Top-Line Efficacy and Safety Results.

Baldwin & Obenauf Scores a Trifecta of Tellys for Fortune 500 Clients

Retrieved on: 
Wednesday, May 31, 2023
Branded content, Media.Monks, BBC, RYOT, Dow Jones, PBS Digital Studios, BNO, Finance, Silver, Creativity, Indian Telly Awards, BET, Vimeo, ESPN Films, NASA, Adobe, Television, A&E Networks, Hearst Communications, FEMA, Verizon Communications, BMS, BBC World Service, Digital, 20th Digital Studio, Netflix, National Geographic Society, Complex Networks, PBS, Partizan, BritBox, Nickelodeon, Airbnb, The Walt Disney Company, Paramount

SOMERVILLE, N.J., May 31, 2023 /PRNewswire/ -- Baldwin & Obenauf, Inc. (BNO) announces that the creative agency won multiple awards in Branded Content categories for videos produced for three of its Fortune 500 clients in the record breaking 44th Annual Telly Awards. Mastercard: Tap on Phone earned a Silver Telly Award in the Financial Services/Banking category; and BMS: This is Where it Gets Interesting and Verizon: Retail Rockstars both earned Bronze among all Recruitment videos.

Key Points: 
  • SOMERVILLE, N.J., May 31, 2023 /PRNewswire/ -- Baldwin & Obenauf, Inc. (BNO) announces that the creative agency won multiple awards in Branded Content categories for videos produced for three of its Fortune 500 clients in the record breaking 44th Annual Telly Awards.
  • "Producing engaging video content is also creatively stimulating and fun for our team and our clients.
  • "The caliber of the work this season coming from creators such as BNO truly has reflected the theme of breaking out and standing out," said Tellys Executive Director Sabrina Dridje.
  • The full list of the 44th Annual Telly Awards winners can be found at www.tellyawards.com/winners .

Baldwin & Obenauf Named to Inc's Best Workplaces of 2023

Retrieved on: 
Thursday, May 11, 2023
Culture, Trust, Team Dynamics, BNO, Creativity, YMCA Training, Inc. (Boston), Inc., Growth, Johnson & Johnson, 100 Best Workplaces in Europe, Nursing, Management

SOMERVILLE, N.J., May 11, 2023 /PRNewswire/ -- Creative agency Baldwin & Obenauf, Inc. (BNO) today announced that the company has been named to Inc's annual Best Workplaces list. With over 40 years in business, BNO also earned special recognition in the Enduring Impact category. The list is the result of a comprehensive measurement of American companies that have excelled in creating exceptional workplaces and company culture.

Key Points: 
  • SOMERVILLE, N.J., May 11, 2023 /PRNewswire/ -- Creative agency Baldwin & Obenauf, Inc. (BNO) today announced that the company has been named to Inc's annual Best Workplaces list.
  • Named to Inc's Best Workplaces of 2023, creative agency BNO earns special recognition for Enduring Impact.
  • "It's an honor to be recognized among Inc's Best Workplaces, a testament to the dedication and creativity of our entire team."
  • "Being named to Best Workplaces is an honor that only a small fraction of companies have been able to claim," says Inc.